Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.

There was a disproportionate association between SGLT2 inhibitors and renal cancer, which supports the current meta-analysis results indicating an increased risk of renal cancer associated with SGLT2 inhibitors.